Aduro Biotech Reports Partial Clinical Hold to Pause Enrollment in LADD Trials
--Current Clinical Trial Patients Are Continuing to Receive LADD Treatment-- --Company to Host Conference Call Today at 6 a.m. PT/9 a.m. ET-- BERKELEY, Calif., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical …